Stock Analiz

Adaptive Biotechnologies Corp (ADPT) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Adaptive Biotechnologies’s revenue went from $38M in fiscal 2017 to $277M in fiscal 2025, growth of about 28.0% a year.

Net income in fiscal 2025 was -$59M, a net margin of -21.5%; the best year in this period was 2017 with -$43M.

Over the twelve months to September 30, 2026, revenue was $298M and net income -$71M.

Free cash flow was -$49M in fiscal 2025 and positive in 1 of the 9 years shown.

The diluted share count rose 1144% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $38M172018: $56M182019: $85M192020: $98M202021: $154M212022: $185M222023: $170M232024: $179M242025: $277M25$277M
Net income
2017: -$43M172018: -$46M182019: -$69M192020: -$146M202021: -$207M212022: -$200M222023: -$225M232024: -$159M242025: -$59M25-$59M
Free cash flow
2017: -$37M172018: -$39M182019: $194M192020: -$168M202021: -$254M212022: -$200M222023: -$167M232024: -$99M242025: -$49M25-$49M
EPS (diluted)
2017: $-3.50172018: $-3.67182019: $-1.01192020: $-1.11202021: $-1.48212022: $-1.40222023: $-1.56232024: $-1.08242025: $-0.3925$-0.39

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$298M$277M$179M$170M$185M$154M$98M$85M$56M$38M
Gross profit$221M$206M$107M$95M$127M$105M$76M$63M$36M$23M
Operating income-$48M-$57M-$163M-$227M-$200M-$209M-$153M-$78M-$50M-$44M
Net income-$71M-$59M-$159M-$225M-$200M-$207M-$146M-$69M-$46M-$43M
EPS (diluted)$-0.45$-0.39$-1.08$-1.56$-1.40$-1.48$-1.11$-1.01$-3.67$-3.50
R&D$83M$94M$103M$122M$142M$142M$116M$71M$39M$32M
Revenue growth—+54.8%+5.1%−8.1%+20.1%+56.9%+15.7%+52.8%+44.8%—

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow-$4M-$46M-$95M-$156M-$184M-$193M-$150M$205M-$32M-$35M
Capital spending-$5M-$3M-$4M-$11M-$16M-$62M-$19M-$11M-$6M-$2M
Free cash flow-$9M-$49M-$99M-$167M-$200M-$254M-$168M$194M-$39M-$37M
Dividends paid—$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$46M$51M$54M$63M$55M$43M$25M$13M$11M$7M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$227M$222M$346M$498M$353M$688M$577M$165M—
Debt—$210M$223M$229M$233M$112M$108M———
Equity—$219M$203M$308M$464M$604M$743M$571M-$258M-$225M
Total assets—$513M$539M$661M$857M$923M$1.1B$912M$333M—
Shares (diluted)187M152M147M144M143M140M131M69M13M12M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin74.2%74.2%59.7%55.6%68.8%68.1%77.1%73.8%64.7%59.2%
Operating margin-16.2%-20.6%-90.8%-133.3%-108.0%-135.4%-155.3%-92.2%-89.4%-115.7%
Net margin-23.7%-21.5%-89.1%-132.3%-108.0%-134.3%-148.6%-80.7%-83.4%-111.4%
FCF margin-3.0%-17.7%-55.2%-98.1%-108.1%-164.9%-171.3%228.3%-69.3%-97.0%
ROIC—-13.3%-38.2%-42.2%-22.7%-23.1%-14.2%-10.8%——
ROE—-27.2%-78.7%-73.0%-43.1%-34.3%-19.7%-12.0%18.0%19.1%

Frequently asked questions

What is Adaptive Biotechnologies’s annual revenue?

$277M in fiscal 2025 and $298M over the twelve months to September 30, 2026.

How much profit does Adaptive Biotechnologies make?

Net income was -$59M in fiscal 2025 (net margin -21.5%).

Is Adaptive Biotechnologies’s revenue growing?

Yes: revenue rose 54.8% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.